title: Prediction of long-term treatment response to selective serotonin reuptake inhibitors (SSRIs) using scalp and source loudness dependence of auditory evoked potentials (LDAEP) analysis in patients with major depressive disorder.
abstract: BACKGROUND
  Animal and clinical studies have demonstrated that the loudness dependence of auditory evoked potentials (LDAEP) is inversely related to central serotonergic activity, with a high LDAEP reflecting weak serotonergic neurotransmission and vice versa, though the findings in humans have been less consistent. In addition, a high pretreatment LDAEP appears to predict a favorable response to antidepressant treatments that augment the actions of serotonin. The aim of this study was to test whether the baseline LDAEP is correlated with response to long-term maintenance treatment in patients with major depressive disorder (MDD).
  
  
  METHODS
  Scalp N1, P2 and N1/P2 LDAEP and standardized low resolution brain electromagnetic tomography-localized N1, P2, and N1/P2 LDAEP were evaluated in 41 MDD patients before and after they received antidepressant treatment (escitalopram (n = 32, 10.0 ± 4.0 mg/day), sertraline (n = 7, 78.6 ± 26.7 mg/day), and paroxetine controlled-release formulation (n = 2, 18.8 ± 8.8 mg/day)) for more than 12 weeks. A treatment response was defined as a reduction in the Beck Depression Inventory (BDI) score of >50% between baseline and follow-up.
  
  
  RESULTS
  The responders had higher baseline scalp P2 and N1/P2 LDAEP than nonresponders (p = 0.017; p = 0.036). In addition, changes in total BDI score between baseline and follow-up were larger in subjects with a high baseline N1/P2 LDAEP than those with a low baseline N1/P2 LDAEP (p = 0.009). There were significantly more responders in the high-LDAEP group than in the low-LDAEP group (p = 0.041).
  
  
  CONCLUSIONS
  The findings of this study reveal that a high baseline LDAEP is associated with a clinical response to long-term antidepressant treatment.
authors: Department of Psychiatry, Seoul Eunpyeong Hospital, 90, Baengnyeonsan-ro, Eunpyeong-gu, Seoul 122-913, Korea. punzza91@naver.com.
authors: Bun-Hee
authors: BH
authors: Lee
authors: Department of Psychiatry, Ilsan Paik Hospital, Inje University College of Medicine, 2240, Daehwa-dong, Ilsanseo-gu, Goyang 411-706, Korea. medipark@hanmail.net.
authors: Young-Min
authors: YM
authors: Park
authors: Department of Psychiatry, Ilsan Paik Hospital, Inje University College of Medicine, 2240, Daehwa-dong, Ilsanseo-gu, Goyang 411-706, Korea. lshpss@hanmail.net.|Clinical Emotion and Cognition Research Laboratory, Inje University, Goyang 411-706, Korea. lshpss@hanmail.net.
authors: Seung-Hwan
authors: SH
authors: Lee
authors: Clinical Emotion and Cognition Research Laboratory, Inje University, Goyang 411-706, Korea. miseon@bme.hanyang.ac.kr.|Department of Biomedical Engineering, Hanyang University, Seoul 133-791, Korea. miseon@bme.hanyang.ac.kr.
authors: Miseon
authors: M
authors: Shim
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004569:Electroencephalography; D005072:Evoked Potentials, Auditory / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012535:Scalp / Q000187:drug effects / Q000503:physiopathology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors